Translational Genomics Research Institute (TGen)

aka TGen, City of Hope TGen, HonorHealth Research Institute

Arizona genomics institute, part of City of Hope, whose pancreatic cancer programme under Daniel Von Hoff produced the MPACT trial that established nab-paclitaxel plus gemcitabine.

The Translational Genomics Research Institute (TGen) is a non-profit genomics research institute in Phoenix, an affiliate of City of Hope since 2016. Its clinical programme, run with the HonorHealth Research Institute in Scottsdale, was led by Daniel Von Hoff, who was first author of the 2013 New England Journal of Medicine report of MPACT, in which nab-paclitaxel plus gemcitabine lengthened survival in metastatic pancreatic cancer. TGen also runs precision medicine programmes in paediatric cancer and glioblastoma.